Published in Semin Oncol on August 01, 2006
MYC on the path to cancer. Cell (2012) 8.65
Structures, folding patterns, and functions of intramolecular DNA G-quadruplexes found in eukaryotic promoter regions. Biochimie (2008) 2.38
Non-B DNA structure-induced genetic instability and evolution. Cell Mol Life Sci (2009) 2.37
Conserved elements with potential to form polymorphic G-quadruplex structures in the first intron of human genes. Nucleic Acids Res (2008) 2.27
Structure of the Hybrid-2 type intramolecular human telomeric G-quadruplex in K+ solution: insights into structure polymorphism of the human telomeric sequence. Nucleic Acids Res (2007) 2.23
Genomic distribution and functional analyses of potential G-quadruplex-forming sequences in Saccharomyces cerevisiae. Nucleic Acids Res (2007) 1.98
Polymorphism of human telomeric quadruplex structures. Biochimie (2008) 1.89
c-Myc and cancer metabolism. Clin Cancer Res (2012) 1.60
A G-rich sequence within the c-kit oncogene promoter forms a parallel G-quadruplex having asymmetric G-tetrad dynamics. J Am Chem Soc (2009) 1.40
Sequence occurrence and structural uniqueness of a G-quadruplex in the human c-kit promoter. Nucleic Acids Res (2007) 1.24
Therapeutic strategies to inhibit MYC. Cold Spring Harb Perspect Med (2014) 1.19
c-MYC promoter G-quadruplex formed at the 5'-end of NHE III1 element: insights into biological relevance and parallel-stranded G-quadruplex stability. Nucleic Acids Res (2011) 1.18
Targeting human gastrointestinal stromal tumor cells with a quadruplex-binding small molecule. J Med Chem (2009) 1.15
Amplitude modulation of androgen signaling by c-MYC. Genes Dev (2013) 1.08
Molecular cloning of the human platelet-derived growth factor receptor beta (PDGFR-beta) promoter and drug targeting of the G-quadruplex-forming region to repress PDGFR-beta expression. Biochemistry (2010) 1.06
The i-motif in the bcl-2 P1 promoter forms an unexpectedly stable structure with a unique 8:5:7 loop folding pattern. J Am Chem Soc (2009) 1.04
Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma. Haematologica (2010) 1.00
Genome-wide colonization of gene regulatory elements by G4 DNA motifs. Nucleic Acids Res (2009) 0.97
The role of G-quadruplex/i-motif secondary structures as cis-acting regulatory elements. Pure Appl Chem (2010) 0.94
Genomic c-Myc quadruplex DNA selectively kills leukemia. Mol Cancer Ther (2011) 0.89
Molecular modeling and biophysical analysis of the c-MYC NHE-III1 silencer element. J Mol Model (2007) 0.86
Zinc protoporphyrin regulates cyclin D1 expression independent of heme oxygenase inhibition. J Biol Chem (2009) 0.86
I-motif structures formed in the human c-MYC promoter are highly dynamic--insights into sequence redundancy and I-motif stability. PLoS One (2010) 0.85
Modulating the functional contributions of c-Myc to the human endothelial cell cyclic strain response. J Vasc Res (2009) 0.82
Biophysical characterization of an ensemble of intramolecular i-motifs formed by the human c-MYC NHE III1 P1 promoter mutant sequence. Biophys J (2010) 0.82
HIV-1 transcriptional silencing caused by TRIM22 inhibition of Sp1 binding to the viral promoter. Retrovirology (2015) 0.80
Anticancer activity of cationic porphyrins in melanoma tumour-bearing mice and mechanistic in vitro studies. Mol Cancer (2014) 0.80
Structural and affinity analyses of g-quadruplex DNA aptamers for camptothecin derivatives. Pharmaceuticals (Basel) (2013) 0.78
Ion-dependent conformational switching by a DNA aptamer that induces remyelination in a mouse model of multiple sclerosis. Nucleic Acids Res (2012) 0.78
GC-elements controlling HRAS transcription form i-motif structures unfolded by heterogeneous ribonucleoprotein particle A1. Sci Rep (2015) 0.78
Therapeutic aspects of c-MYC signaling in inflammatory and cancerous colonic diseases. World J Gastroenterol (2016) 0.77
Classification of g-quadruplex DNA on the basis of the quadruplex twist angle and planarity of g-quartets. Acta Naturae (2010) 0.76
Transfecting RNA quadruplexes results in few transcriptome perturbations. RNA Biol (2012) 0.76
TMPyP4 promotes cancer cell migration at low doses, but induces cell death at high doses. Sci Rep (2016) 0.75
Discovery of a Family of Genomic Sequences Which Interact Specifically with the c-MYC Promoter to Regulate c-MYC Expression. PLoS One (2016) 0.75
An XIST-related small RNA regulates KRAS G-quadruplex formation beyond X-inactivation. Oncotarget (2016) 0.75
Quinazoline derivative QPB-15e stabilizes the c-myc promoter G-quadruplex and inhibits tumor growth in vivo. Oncotarget (2016) 0.75
Keeping those telomeres short! an innovative intratumoral long-term drug delivery system. J Cancer Res Clin Oncol (2014) 0.75
A novel G-quadruplex motif in the Human MET promoter region. Biosci Rep (2017) 0.75
Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell (2012) 7.57
Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med (2009) 7.23
American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol (2004) 4.48
Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res (2011) 4.05
Human telomeric sequence forms a hybrid-type intramolecular G-quadruplex structure with mixed parallel/antiparallel strands in potassium solution. Nucleic Acids Res (2006) 3.87
Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther (2007) 3.61
Solution structure of the biologically relevant G-quadruplex element in the human c-MYC promoter. Implications for G-quadruplex stabilization. Biochemistry (2005) 3.41
The dynamic character of the G-quadruplex element in the c-MYC promoter and modification by TMPyP4. J Am Chem Soc (2004) 3.19
An intramolecular G-quadruplex structure with mixed parallel/antiparallel G-strands formed in the human BCL-2 promoter region in solution. J Am Chem Soc (2006) 2.91
Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res (2002) 2.71
Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res (2002) 2.55
Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol (2005) 2.53
The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo. Mol Cancer Ther (2002) 2.39
Structure of the Hybrid-2 type intramolecular human telomeric G-quadruplex in K+ solution: insights into structure polymorphism of the human telomeric sequence. Nucleic Acids Res (2007) 2.23
Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. Cancer Res (2010) 2.18
Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. Clin Cancer Res (2011) 2.12
Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification. Cancer Biol Ther (2008) 2.09
NMR solution structure of the major G-quadruplex structure formed in the human BCL2 promoter region. Nucleic Acids Res (2006) 2.03
Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis. Cancer Res (2009) 1.98
Polymorphism of human telomeric quadruplex structures. Biochimie (2008) 1.89
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. N Engl J Med (2015) 1.75
Structure of the intramolecular human telomeric G-quadruplex in potassium solution: a novel adenine triple formation. Nucleic Acids Res (2007) 1.72
PRL phosphatases as potential molecular targets in cancer. Mol Cancer Ther (2005) 1.67
The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer. Mol Cancer Ther (2004) 1.65
Perineural invasion and associated pain in pancreatic cancer. Nat Rev Cancer (2011) 1.64
RuleMonkey: software for stochastic simulation of rule-based models. BMC Bioinformatics (2010) 1.49
Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. J Transl Med (2009) 1.48
Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Mol Cancer Ther (2006) 1.41
Design and synthesis of an expanded porphyrin that has selectivity for the c-MYC G-quadruplex structure. J Am Chem Soc (2005) 1.40
Translational therapeutic opportunities in ductal adenocarcinoma of the pancreas. Clin Cancer Res (2012) 1.33
Novel DNA bis-intercalation by MLN944, a potent clinical bisphenazine anticancer drug. J Biol Chem (2004) 1.31
Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells. Clin Cancer Res (2009) 1.29
Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer. J Med Chem (2010) 1.27
Structure of a two-G-tetrad intramolecular G-quadruplex formed by a variant human telomeric sequence in K+ solution: insights into the interconversion of human telomeric G-quadruplex structures. Nucleic Acids Res (2009) 1.25
Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. Mol Cancer Ther (2004) 1.24
Targeting Aurora-2 kinase in cancer. Mol Cancer Ther (2003) 1.23
Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer. Mol Cancer Ther (2010) 1.20
c-MYC promoter G-quadruplex formed at the 5'-end of NHE III1 element: insights into biological relevance and parallel-stranded G-quadruplex stability. Nucleic Acids Res (2011) 1.18
Simulation of large-scale rule-based models. Bioinformatics (2009) 1.18
Solution structure of a 2:1 quindoline-c-MYC G-quadruplex: insights into G-quadruplex-interactive small molecule drug design. J Am Chem Soc (2011) 1.17
Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells. Clin Cancer Res (2011) 1.17
Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look. Cancer Discov (2011) 1.17
Identification of somatic mutations in cancer through Bayesian-based analysis of sequenced genome pairs. BMC Genomics (2013) 1.13
Tubulin-associated drug targets: Aurora kinases, Polo-like kinases, and others. Semin Oncol (2006) 1.12
Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer. Mol Cell Biochem (2011) 1.12
Quartets in G-major. The First International Meeting on Quadruplex DNA. EMBO Rep (2007) 1.11
Gene expression profiling-based identification of cell-surface targets for developing multimeric ligands in pancreatic cancer. Mol Cancer Ther (2008) 1.10
A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer. Breast Cancer Res Treat (2014) 1.08
A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies. Clin Cancer Res (2002) 1.07
The dynamic character of the BCL2 promoter i-motif provides a mechanism for modulation of gene expression by compounds that bind selectively to the alternative DNA hairpin structure. J Am Chem Soc (2014) 1.06
Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells. Cancer Res (2006) 1.06
A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors. Clin Cancer Res (2006) 1.06
Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial. Am J Clin Oncol (2008) 1.05
CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy. Mol Cancer Ther (2012) 1.05
Skeletal metastases in pancreatic cancer: a retrospective study and review of the literature. Yale J Biol Med (2009) 1.03
Down-regulation of Yes Associated Protein 1 expression reduces cell proliferation and clonogenicity of pancreatic cancer cells. PLoS One (2012) 1.02
Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial. Cancer Chemother Pharmacol (2006) 1.02
Tumor-stromal interactions in pancreatic cancer. Crit Rev Oncog (2013) 1.01
A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors. Clin Cancer Res (2012) 1.01
UA62784, a novel inhibitor of centromere protein E kinesin-like protein. Mol Cancer Ther (2009) 1.01
Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. Invest New Drugs (2010) 1.00
A historical perspective of anthracycline cardiotoxicity. Heart Fail Clin (2011) 0.99
Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-induced gene in pancreatic cancer. Pancreas (2008) 0.99
A pilot study using next-generation sequencing in advanced cancers: feasibility and challenges. PLoS One (2013) 0.98
Quiescin sulfhydryl oxidase 1 promotes invasion of pancreatic tumor cells mediated by matrix metalloproteinases. Mol Cancer Res (2011) 0.98
Small interfering RNA-mediated knockdown of PRL phosphatases results in altered Akt phosphorylation and reduced clonogenicity of pancreatic cancer cells. Mol Cancer Ther (2008) 0.97
A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination. Cancer Chemother Pharmacol (2010) 0.96
Adrenocortical carcinoma survival rates correlated to genomic copy number variants. Mol Cancer Ther (2008) 0.96
Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells. Cancer Lett (2012) 0.95
Paired tumor and normal whole genome sequencing of metastatic olfactory neuroblastoma. PLoS One (2012) 0.95
The impact of concomitant medication use on patient eligibility for phase I cancer clinical trials. J Cancer (2012) 0.94
Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics. Invest New Drugs (2009) 0.93
Molecular characterization of interdigitating dendritic cell sarcoma. Rare Tumors (2010) 0.92
Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer. Biochemistry (2011) 0.91
High-throughput RNAi screening identifies a role for TNK1 in growth and survival of pancreatic cancer cells. Mol Cancer Res (2011) 0.91
Comparing Aurora A and Aurora B as molecular targets for growth inhibition of pancreatic cancer cells. Mol Cancer Ther (2006) 0.91
Progression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials. J Cancer (2011) 0.91
Functional genomics reveals diverse cellular processes that modulate tumor cell response to oxaliplatin. Mol Cancer Res (2010) 0.91
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer. Clin Cancer Res (2013) 0.90
Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer. Biochem Biophys Res Commun (2011) 0.90
A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms. Clin Cancer Res (2004) 0.90
SnapShot: pancreatic cancer. Cancer Cell (2013) 0.90
Tubulin-associated proteins: Aurora and Polo-like kinases as therapeutic targets in cancer. Curr Oncol Rep (2008) 0.90
The major G-quadruplex formed in the human BCL-2 proximal promoter adopts a parallel structure with a 13-nt loop in K+ solution. J Am Chem Soc (2014) 0.90
Solution structure of the major G-quadruplex formed in the human VEGF promoter in K+: insights into loop interactions of the parallel G-quadruplexes. Nucleic Acids Res (2013) 0.90
DNA minor groove binders: back in the groove. Cancer Treat Rev (2009) 0.89
Hydrophilic camptothecin analogs that form extremely stable cleavable complexes with DNA and topoisomerase I. Cancer Res (2004) 0.89
Antitubercular constituents of Valeriana laxiflora. Planta Med (2004) 0.88
Specification, annotation, visualization and simulation of a large rule-based model for ERBB receptor signaling. BMC Syst Biol (2012) 0.88
XR5944: A potent inhibitor of estrogen receptors. Mol Cancer Ther (2007) 0.88
Kinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitors. Biochem Pharmacol (2011) 0.87
A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies. Clin Cancer Res (2002) 0.87
Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer. Urol Oncol (2009) 0.87
Topoisomerase I-DNA complex stability induced by camptothecins and its role in drug activity. Curr Med Chem Anticancer Agents (2004) 0.86
Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agents. Semin Oncol (2006) 0.86
I-motif structures formed in the human c-MYC promoter are highly dynamic--insights into sequence redundancy and I-motif stability. PLoS One (2010) 0.85
Sequence, stability, and structure of G-quadruplexes and their interactions with drugs. Curr Protoc Nucleic Acid Chem (2012) 0.85
Basal cell nevus syndrome: a brave new world. Arch Dermatol (2010) 0.85
The major G-quadruplex formed in the human platelet-derived growth factor receptor β promoter adopts a novel broken-strand structure in K+ solution. J Am Chem Soc (2012) 0.84